New research indicates that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Research printed in a prominent medical journal shows that while obese individuals can lose a large proportion of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using these medications should be aware of the risk of fast weight regain when the treatment concludes," warns researcher Dr. Susan Jebb.
Such speed of regain implies a return to original weight in about a year and a half.
Comparing Treatments
The research, which reviewed 37 of trials involving thousands of patients, compared the outcomes of the injectable medications with older methods.
The team note that people who lose weight through dieting typically have a more gradual weight regain—around 100 grams monthly—once they finish.
The Reason for the Fast Regain
Experts suggest the mode of action of the jabs accounts for the amplified weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of the hormone concentrations several times higher than normal may cause the body to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' results in hunger is uncontrolled, making overeating much more probable."
A Lifelong Condition?
The NHS advise the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians argue that, given the significant potential of weight regain, the therapy might need to be life-long.
This opinion is reinforced by pharmaceutical companies, who say that the results "highlight the long-term nature of obesity," similar to managing conditions like hypertension.
User Testimonies
Individuals who have come off the jabs describe a intense resurgence of appetite.
"It was like a trigger flipping and you're instantly starving," described an individual.
This challenge is exacerbated if patients have not adopted lasting dietary or behavioural changes during treatment.
Growing Interest
Recent estimates indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Use is greater among women than men.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, experts emphasize that while the jabs are effective agents for shedding pounds, they are not a permanent fix and lasting health benefits hinges on ongoing lifestyle management.
